Humanigen CEO Receives PharmaVOICE 100 Red Jacket Award
August 11, 2017
BRISBANE, Calif., Aug. 11, 2017 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced that Cameron Durrant, MD, chairman and CEO, has been named a PharmaVOICE 100 Red Jacket Award honoree as part of the annual PharmaVOICE 100.
The PharmaVOICE 100 Red Jacket Award is a prestigious annual distinction that serves as a 'hall of fame' for executives who have been recognized multiple times in the PharmaVOICE 100, the publication's annual list of inspiring industry leaders. PharmaVOICE 100 Red Jacket Award winners are selected as individuals who have shown a new kind of leadership, such as driving new ways of thinking, acting and leading; creating new opportunities from the 'impossible'; having persistence of vision; and inspiring leaders for today and tomorrow.
"I am honored and grateful to be inducted into such an influential circle of leaders as the PharmaVOICE 100 Red Jacket Award," said Dr. Durrant. "Finding new ways forward requires the persistence and resilience to execute and deliver them. This honor reflects the determination and forward-thinking mindset of our talented team at Humanigen, as we continue to execute on our priorities to help neglected and rare disease patients."
Since January 2016, Dr. Durrant has led the transformation of Humanigen through significant operational, reputational and legal hurdles. Dr. Durrant is a five-time PharmaVOICE 100 honoree. To read the 2017 PharmaVOICE100 Red Jacket Award profiles, visit www.pharmavoice.com.
Humanigen, Inc. is a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative, accelerated business models. Lead compounds in the portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). For more information, visit www.humanigen.com.
Source: Humanigen, Inc.
Released August 11, 2017